115195
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
肺气肿对接受 ICI 治疗 NSCLC 患者疗效和免疫相关肺炎风险的影响：生存改善但毒性增加的 Meta 分析
Authors Li W, Liu S, Yu X, Lan W, Liu X
Received 25 September 2025
Accepted for publication 22 December 2025
Published 9 January 2026 Volume 2026:21 569504
DOI https://doi.org/10.2147/COPD.S569504
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Editor who approved publication: Prof. Dr. Richard Russell
Wenjuan Li, Shilan Liu, Xiaodan Yu, Wenyi Lan, Xiao Liu
Department of Pulmonary and Critical Care Medicine, Chengdu Fifth People’s Hospital, Chengdu, 611130, People’s Republic of China
Correspondence: Xiao Liu, Department of Pulmonary and Critical Care Medicine, Chengdu Fifth People’s Hospital, Chengdu, 611130, People’s Republic of China, Email lxzl111@126.com
Purpose: To identify the impact of CT-defined emphysema on efficacy and immune checkpoint inhibitor-related pneumonitis (ICIP) risk among non-small cell lung cancer (NSCLC) patients who receive ICIs.
Methods: PubMed, EMBASE, Web of Science and CNKI databases were searched up to January 8, 2025. Primary outcome was the therapeutic efficacy including the progression-free survival (PFS), overall survival (OS), complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD), objective response rate (ORR) and disease control rate (DCR). Second outcome was the ICIP. The hazard ratio (HR) or odds ratio (OR) with 95% confidence interval (CI) were combined.
Results: Nine studies with 1076 cases were included. Pooled results demonstrated that the presence of emphysema was significantly associated with improved PFS (HR = 0.43, 95% CI: 0.28– 0.67, P < 0.001), OS (HR = 0.43, 95% CI: 0.25– 0.75, P = 0.003), PR (OR = 2.10, 95% CI: 1.18– 3.75, P = 0.012), PD (OR = 0.60, 95% CI: 0.43– 0.83, P = 0.002) and DCR (OR = 1.48, 95% CI: 1.14– 1.94, P = 0.004). However, emphysema was associated with increased incidence of ICIP (OR = 1.32, 95% CI: 1.15– 1.53, P < 0.001).
Conclusion: Based on available evidence, CT-defined emphysema indicates better therapeutic efficacy with longer PFS and OS, but increased risk of ICIP among NSCLC patients receiving ICIs. These findings suggest emphysema may guide personalized immunotherapy decisions in NSCLC.
Keywords: non-small cell lung cancer, emphysema, therapeutic efficacy, immune-related pneumonitis, immune checkpoint inhibitors
Department of Pulmonary and Critical Care Medicine, Chengdu Fifth People’s Hospital, Chengdu, 611130, People’s Republic of China
Correspondence: Xiao Liu, Department of Pulmonary and Critical Care Medicine, Chengdu Fifth People’s Hospital, Chengdu, 611130, People’s Republic of China, Email lxzl111@126.com
Purpose: To identify the impact of CT-defined emphysema on efficacy and immune checkpoint inhibitor-related pneumonitis (ICIP) risk among non-small cell lung cancer (NSCLC) patients who receive ICIs.
Methods: PubMed, EMBASE, Web of Science and CNKI databases were searched up to January 8, 2025. Primary outcome was the therapeutic efficacy including the progression-free survival (PFS), overall survival (OS), complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD), objective response rate (ORR) and disease control rate (DCR). Second outcome was the ICIP. The hazard ratio (HR) or odds ratio (OR) with 95% confidence interval (CI) were combined.
Results: Nine studies with 1076 cases were included. Pooled results demonstrated that the presence of emphysema was significantly associated with improved PFS (HR = 0.43, 95% CI: 0.28– 0.67, P < 0.001), OS (HR = 0.43, 95% CI: 0.25– 0.75, P = 0.003), PR (OR = 2.10, 95% CI: 1.18– 3.75, P = 0.012), PD (OR = 0.60, 95% CI: 0.43– 0.83, P = 0.002) and DCR (OR = 1.48, 95% CI: 1.14– 1.94, P = 0.004). However, emphysema was associated with increased incidence of ICIP (OR = 1.32, 95% CI: 1.15– 1.53, P < 0.001).
Conclusion: Based on available evidence, CT-defined emphysema indicates better therapeutic efficacy with longer PFS and OS, but increased risk of ICIP among NSCLC patients receiving ICIs. These findings suggest emphysema may guide personalized immunotherapy decisions in NSCLC.
Keywords: non-small cell lung cancer, emphysema, therapeutic efficacy, immune-related pneumonitis, immune checkpoint inhibitors